P336 French prospective, longitudinal observational study of the therapeutic management of mild to moderate ulcerative colitis (Optimum study): follow-up at 3 years
S. Nahon*1, G. Bonnaud2, F. Bahbah3
1Centre Hospitalier Le Raincy, Montfermeil, France, 2Ambroise Paré Private hospital, IBD Unit, Toulouse, France, 3Ferring Pharmaceuticals, Gentilly, France
The aims of the OPTIMUM (Observational, Prospective, Longitudinal Study of the Therapeutic Management of Mild to Moderate Ulcerative Colitis), set up in France in 2011, are to describe the progression and methods of therapeutic management of mild to moderate ulcerative colitis (UC) and to assess the remission rate and duration, as well as to determine the prognostic factors for relapse at 3 years.
In total, 812 patients experiencing a flare-up of mild to moderate UC were enrolled by 130 gastroenterologists, 64% of whom were in private practice. The patient data are recorded in an electronic CRF during consultations conducted as part of regular follow-up. The intermediate and descriptive analysis of the data available as of June 30, 2015 is presented below, and it represents 364 (45%) patients who had a visit at 3 years (as of October 30, 2015, data for 489 [60%] patients who had a visit at 3 years were available).
During the 3 years of follow-up, 317 (39%) patients had at least 1 relapse, and 55 (7%) had at least 1 hospitalisation related to UC. At 3 years of follow-up, 298 (82%) were in remission according to the UCCS. At enrolment, 583 (72%) patients were receiving treatment for UC; 432 subjects were treated with oral 5-ASA, which was combined with rectal 4- or 5-ASA in 131 patients. At the consultation at 3 years, 292 (80%) patients were receiving treatment for UC; 211 patients were treated with oral 5-ASA, combined with rectal 4- or 5-ASA in 37 patients. The proportion of patients treated with 5-ASA, immunosuppressants and anti-TNFs at the visits at 1 year, 2 years, and 3 years is presented in the following table. One notes an improvement of adherence, as well as stability, of the UCCS score over the 3 years of follow-up.
Table 1. Treatment, adherence to the UC treatment and UCCS Score for UC activity
In this large cohort of patients with mild to moderate UC, inducing remission and maintenance are mainly based on treatment with 5-ASA. At 3 years of follow-up, 72% of treated patients are receiving 5-ASA and 82% are in remission.